Home » D Pharm Reports Stroke Treatment Safety Approval

D Pharm Reports Stroke Treatment Safety Approval

July 21, 2011

D Pharm reported the Data and Safety Monitoring Board recommends the company’s ischemic stroke treatment DP-b99 after it proved safe in a Phase III clinical trial.
Globes

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

D Pharm Reports Stroke Treatment Safety Approval

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements